From March 18 to 20, 2025, the "China (Suzhou) Innovative Drug Medical Conference," hosted by the China Medical Innovation Promotion Association (CMAC), will take place at the Suzhou International Expo Center. Centered on the theme "Consolidating Medical Knowledge, Converging Innovative Power," the conference will bring together global pharmaceutical experts to engage in over 100 thematic discussions on cutting-edge topics such as drug regulation, medical affairs, AI R&D, and global synchronized registration, fostering an international exchange platform for pharmaceutical innovation.
Glodom will showcase its multilingual services, data services, and AI-driven solutions at the event, highlighting its full-chain language service capabilities. Located at Booth B28, Glodom will present innovative achievements in the deep integration of AI technology and life sciences, aiming to help the global pharmaceutical industry overcome language and cultural barriers. Visitors are welcome to explore collaboration opportunities.
As a professional language service provider with over two decades of expertise, Glodom not only excels in multilingual localization but also integrates AI-powered language solutions into the healthcare sector, empowering medical enterprises to achieve "AI+Smart Healthcare" and resolve daily language-related challenges. Additionally, as the official interpreting partner of the conference, Glodom will provide professional simultaneous interpretation support for the core forums.
With a global team covering over 200 languages, Glodom serves the entire pharmaceutical industry chain, including critical scenarios such as patent applications, clinical trials, and regulatory documentation. Leveraging its self-developed AI translation platform and a network of 5,000+ native-level linguists, the company strictly adheres to international regulatory standards (e.g., FDA, EMA, NMPA) and holds dual certifications in ISO 27001 Information Security Management and ISO 9001 Quality Management, ensuring compliance and efficiency.
At the conference, Glodom will emphasize its innovations in merging AI with life sciences. By customizing data collection and aligning medical parallel corpora, the company has built a multilingual database compliant with ICH (International Council for Harmonisation) standards, laying the foundation for complex document processing. Through algorithm optimization and model training, Glodom enables automated translation and proofreading of intricate documents such as clinical trial protocols and investigator brochures, significantly improving translation efficiency. Customizable API interfaces also allow seamless integration into enterprise workflows, meeting real-time demands for multinational clinical trials and regulatory submissions.
Furthermore, Glodom’s data services are backed by expert teams with an average of five years of industry experience, covering the entire drug R&D lifecycle. The teams support multilingual integration and analysis of real-world data (RWD) through platforms for data annotation, collection, and quality control across 200+ languages. Guided by a four-dimensional evaluation system and machine learning operations (MLOps), Glodom ensures the accuracy and compliance of translations to meet global regulatory requirements.
As China’s pharmaceutical innovation accelerates its global reach, Glodom remains committed to delivering efficient and compliant "Language + Data + AI" solutions for the industry. We warmly invite industry peers to visit Booth B28 at the Suzhou International Expo Center from March 18 to 20 to explore global opportunities in pharmaceutical innovation. Glodom looks forward to collaborating with partners to empower China’s pharmaceutical sector with professional services and create a better medical future for patients worldwide.
